MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Paradigm Biopharmaceuticals continues to edge closer towards starting the pivotal phase III trial for its knee osteoarthritis ...

Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA ...

I can tell you that VDPHL01 has a unique profile unlike current FDA-approved treatments, which are associated with cardiac ...

Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...

Paradigm Biopharmaceuticals has selected Advanced Clinical as the CRO to support its Phase III trial, PARA_OA_012, focused on ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

“We are delighted to partner with Advanced Clinical for our pivotal phase III clinical trial, PARA_OA_012,” managing director Paul Rennie said. “Advanced Clinical’s expertise in clinical ...

Viking Therapeutics got the market's attention with robust phase 2 results for VK2735, a potential weight loss therapy.